Seattle Children’s Research Institute becomes the 13th partner actively using the IRO Platform
PHILADELPHIA, PA and LONDON, UK – November 11, 2025 –
Ori Biotech, a leader in cell and gene therapy (CGT) manufacturing technology, today announced a partnership with Seattle Children’s Research Institute (SCRI), one of the nation’s top children’s hospitals and academic research centers, to evaluate the IRO® platform in support of advancing CGT research and clinical development.
Seattle Children’s Research Institute, which contributed to the development and out-licensing of Breyanzi®, will utilize the IRO platform to evaluate how early adoption of automation can accelerate product development, drive enhanced consistency, and enable scalable manufacturing of cell and gene therapy programs. By introducing best-of-breed automation into its research and development environment, SCRI aims to enhance its growing internal pipeline and better support investigator partners as they advance promising therapies toward clinical and commercial milestones.
“Academic Medical Center pioneers like Seattle Children’s Research Institute play a critical role in moving early scientific discoveries into the therapies patients are waiting for. But too many promising programs stall when legacy manufacturing platforms cannot deliver on the needs of today’s therapies,” said Jason C. Foster, CEO, Ori Biotech. “IRO delivers superior biology and scalability in a best-of-breed platform that sets a new standard for CGT manufacturing. We are excited to support SCRI as they evaluate how early automation can help bring more investigational therapies to more research participants, more quickly and more cost-effectively.”
“At Seattle Children’s Research Institute, our mission is to bring better treatments to children and families who urgently need them,” said Dr. Colleen Delaney, VP and Chief Medical Officer of Seattle Children’s Research Institute. “By exploring Ori’s IRO platform, we are evaluating how advanced automation can enhance translation of the innovative research at SCRI to the bedside and allow us to provide greater support to our local and external CGT partners. We look forward to understanding how IRO can help us accelerate development timelines while maintaining the highest standards of quality and patient focus.”
This collaboration with SCRI highlights Ori’s increasing momentum with 13 active partners worldwide, including Charles River Laboratories, CTMC (a joint venture between Resilience and MD Anderson Cancer Center), ElevateBio, and Kincell, as well as other Global CDMOs and two Tier 1 Pharma companies with experience developing and launching cell therapy products. The rapid rate of adoption since its launch in 2024 further signals the IRO platform as the New Standard in CGT manufacturing. The IRO platform recently received FDA Advanced Manufacturing Technology (AMT) designation, which recognizes its ability to significantly improve reliability, scalability, and product quality, while also providing therapy developers with earlier and more frequent engagement with the FDA.
Together with partners such as Seattle Children’s Research Institute, Ori is working to accelerate the path from development to commercialization for the next generation of cell therapies, to ultimately achieve our shared mission of enabling widespread access to life-saving cell and gene therapies.
To learn more about the IRO platform, visit Oribiotech.com/IRO.
About Ori Biotech
Ori Biotech is a manufacturing technology company on a mission to enable widespread patient access to life-saving cell and gene therapies. IRO®, Ori’s next-generation manufacturing platform, automates better biology, accelerates product development, and enables therapy developers to scale their products’ clinical and commercial impact by seamlessly transitioning from R&D to GMP on one platform. The Ori platform automates cell therapy manufacturing, increasing throughput, improving quality and decreasing costs by combining proprietary hardware, consumables, software, data and analytics.
Launched in 2024, IRO holds an FDA Advanced Manufacturing Technology (AMT) designation, validating the platform as a leading solution for overcoming critical challenges in CGT manufacturing. The designation recognizes IRO’s ability to significantly improve reliability, scalability, and product quality, while providing therapy developers with earlier and more frequent engagement with the FDA to accelerate development and improve patient access.
For news and updates, visit oribiotech.com/news-insights
NOTE: BREYANZI is a trademark of Juno Therapeutics, Inc., a Bristol Myers Squibb company.